Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior.
about
Reversing EphB2 depletion rescues cognitive functions in Alzheimer modelCytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaiseKynurenines in the mammalian brain: when physiology meets pathologyCrystal Structure-Based Selective Targeting of the Pyridoxal 5′-Phosphate Dependent Enzyme Kynurenine Aminotransferase II for Cognitive EnhancementStructure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing InteractionsPsychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behaviorThe impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophreniaGPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapsesThe Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memoryPre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies.Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease.NMDA receptors in GABAergic synapses during postnatal development.Kynurenine aminotransferase III and glutamine transaminase L are identical enzymes that have cysteine S-conjugate β-lyase activity and can transaminate L-selenomethionineThe relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment.Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brainCX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease.Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.PAH particles perturb prenatal processes and phenotypes: protection from deficits in object discrimination afforded by dampening of brain oxidoreductase following in utero exposure to inhaled benzo(a)pyreneNew insights into the metabolism of organomercury compounds: mercury-containing cysteine S-conjugates are substrates of human glutamine transaminase K and potent inactivators of cystathionine γ-lyasePutative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorderProlonged Subdural Infusion of Kynurenic Acid Is Associated with Dose-Dependent Myelin Damage in the Rat Spinal CordInfluence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophreniaKynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice.Ketogenic diet increases concentrations of kynurenic acid in discrete brain structures of young and adult rats.Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge.Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study.Is there a role for immune-to-brain communication in schizophrenia?Toxoplasma gondii and cognitive deficits in schizophrenia: an animal model perspectiveExposure to kynurenic acid during adolescence produces memory deficits in adulthood.The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.Sustained elevation of kynurenic Acid in the cerebrospinal fluid of patients with herpes simplex virus type 1 encephalitis.The treatment of cognitive impairment in schizophrenia.The common inflammatory etiology of depression and cognitive impairment: a therapeutic target.The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malariaKynurenines and Glutamate: Multiple Links and Therapeutic Implications.Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts.
P2860
Q24632892-2F4B6B52-E2CB-4FE6-93DD-BD1629BB72BCQ27001628-71A6B58B-D360-4477-9BDB-C047D800BA6AQ27003296-F163FC6D-5785-40B6-9B50-6382E25B917AQ27663873-103736E5-946E-4A11-A5C9-C78F915892AAQ27684159-F763D1E5-DBC2-43B9-8D5D-4D2E32B5E8EDQ27694728-503F981D-F6E2-4E61-9680-F7E5C9EEC1F1Q28081110-D83B3C9E-369F-48A9-A564-8F6027D05D16Q28535496-F349B2D5-758D-4409-9B4D-2EE5D58FFA4CQ30373328-91CA95E6-9779-4CA4-A1DF-02FF85296ED8Q30504501-BED33538-D462-459C-9465-FE639B0EA07EQ30544793-F8CEF0D9-C9C2-4027-9437-675AC539E5C0Q33572850-1E4BCBCE-2901-478B-8B39-FB4335B3755CQ34207080-8F130289-E98D-448C-BDFD-BC48C7C3D45EQ34291242-A9E4F2EC-5A7E-4036-9362-0DF515700783Q34467450-01033E9A-6817-4F1D-8535-F1C49328AD06Q34662653-B843B2BF-44B3-45CB-B41D-F0550316B1C2Q35003093-C57BB366-3E60-451B-9012-58AC4BF04B33Q35213298-830D9B1C-8248-4F78-8CED-7F0A60F98B36Q35390305-EA10C2CB-266F-4029-85DC-7D6F614D0923Q35626780-BA13B535-546E-41BC-A92B-3806505309F8Q35633926-F240AD28-9B9F-454B-9BEB-1BD9368EFBADQ35647362-F8460E36-79EC-47C1-995B-A7644B9D0325Q35840053-8DE38301-2976-46CE-8C9A-AF16F26F6CAEQ35892576-8991476B-77D9-4AFB-8DA9-DDE85F8354C1Q35923160-82F948D8-45EE-41A4-8C77-5DC0CF2BC17BQ35985369-4AD22D6D-7459-4D86-AD77-C8973A9E9619Q36183347-B7EDA590-125E-49C2-B2A5-6CF8E023C3CCQ36189171-7426C6D6-835D-4BE2-AFA2-204A5C9006BAQ36351021-433A6CBF-912E-4D10-A886-D6FD40142C9AQ36386410-15E79D4F-8A85-4650-ADE5-8D8449BB2420Q36623248-9962A843-7D8D-4123-8FCB-5194AA09E8CFQ37318862-4AAC2DFE-1252-4780-969C-746F48C2F546Q37373503-9C0C7AE9-7C06-4E39-B367-13B46A2108E6Q37813206-8C8E7FBC-3761-42DF-A01E-AA14FE2E15EBQ38245307-66C56A5D-2CA4-480D-A761-FC9B08C5EDF5Q38253558-54029655-9CDC-4CA0-B70C-BB9CE229689CQ38761405-BD649B3B-A445-4447-9057-6E684CFC1E4FQ38849464-E2333B85-BEE8-4B16-96B9-FCADC2B10CA6Q38861843-7872E740-60D1-4BBE-A159-7E6F06A325C1Q38867611-2120ED58-024B-4CB1-84C2-0988CFE987D7
P2860
Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Reduction of endogenous kynure ...... ticity, and cognitive behavior
@nl
Reduction of endogenous kynure ...... icity, and cognitive behavior.
@ast
Reduction of endogenous kynure ...... icity, and cognitive behavior.
@en
type
label
Reduction of endogenous kynure ...... ticity, and cognitive behavior
@nl
Reduction of endogenous kynure ...... icity, and cognitive behavior.
@ast
Reduction of endogenous kynure ...... icity, and cognitive behavior.
@en
prefLabel
Reduction of endogenous kynure ...... ticity, and cognitive behavior
@nl
Reduction of endogenous kynure ...... icity, and cognitive behavior.
@ast
Reduction of endogenous kynure ...... icity, and cognitive behavior.
@en
P2093
P2860
P3181
P356
P1476
Reduction of endogenous kynure ...... icity, and cognitive behavior.
@en
P2093
Edson X Albuquerque
Greg I Elmer
Hui-Qiu Wu
Michelle C Potter
Paolo Guidetti
Richard Bergeron
Robert Schwarcz
P2860
P2888
P304
P3181
P356
10.1038/NPP.2010.39
P407
P577
2010-03-24T00:00:00Z
P5875
P6179
1013139430